Alzheimer’s Drugs Market (2025-2032)
The Alzheimer’s Drugs Market is projected to reach $9.62 billion by 2032 at a CAGR of 9.8% from 2025 to 2032.
- Published
- Sep 2024
- Pages
- 200
- Format
- PDF + Excel
- Report ID
- MR-1264
- Base year
- 2024
- 2032 · FORECAST
- $9.62B
- 2032
- $9.62B
- CAGR 2025–2032
- 9.8%
2024 baseline · 2025–2032 forecast at 9.8% CAGR · hover a bar for the value
Key highlights
The Alzheimer’s Drugs Market is projected to reach $9.62 billion by 2032 at a CAGR of 9.8% from 2025 to 2032.
In 2025, North America is expected to account for the largest share of the 43.0% of Alzheimer’s drugs market. The large share of the region is attributed to the increasing prevalence of Alzheimer’s disease, increasing funding for the development of Alzheimer’s treatment, the presence of key players, the rising number of clinical trials for Alzheimer’s drugs, and favorable reimbursement policies.
Moreover, the market in Asia-Pacific is slated to register the highest growth rate of 11.4% during the forecast period.
Report summary
| Particulars | Details |
|---|---|
| Number of Pages | 200 |
| Format | |
| Forecast Period | 2025-2032 |
| Base Year | 2024 |
| CAGR | 9.8% |
| Estimated Market Size (Value) | $9.62 billion by 2032 |
| Segments Covered | By Drug Type · Cholinesterase Inhibitors · Donepezil · Galantamine · Rivastigmine · NMDA receptor antagonists · Glutamate regulators · Combination Drugs · By Application · Disease Progression · Symptoms Management · Dementia · Insomnia · Other Symptoms · (Note: Other symptoms include loss of spontaneity, depression, hallucination, or paranoia.) |
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, Switzerland, Belgium, and Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentina, Rest of Latin America), and Middle East & Africa (UAE, Saudi Arabia, South Africa, and Rest of Middle East & Africa). |
| Key Companies | The key players operating in the Alzheimer’s drugs market are Biogen (U.S.), Novartis AG (Switzerland), F. Hoffmann-La Roche AG (Switzerland), AbbVie Inc. (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eisai Co., Ltd. (Japan), SUPERNUS PHARMACEUTICALS, INC. (U.S.), H. Lundbeck A/S (Denmark), AC Immune SA (Switzerland), Zydus Lifesciences Limited (India), Johnson & Johnson (U.S.), and Daiichi Sankyo Company (Japan). |
Report overview
Segments covered: drug. Regions: North America, Europe, Asia-Pacific, Latin America.
The growth of this market can be attributed to various factors, such as the increasing burden of Alzheimer's disease globally, rising prevalence of risk factors, increase in research funding, introduction of innovative technologies, increasing number of approvals, and increasing number of clinical trials and pipeline products. Furthermore, growing research activities in developing countries, increase in awareness programs, initiatives by public and private organizations, use of combination drug therapy, and use of biomarkers and imaging techniques for diagnosis and management are expected to offer growth opportunities.
Report infographic
Market dynamics
5 factors across 3 forcesIncreasing Burden of Alzheimer’s Disease Globally
Alzheimer’s is a brain condition that causes a progressive decline in memory, organizing, learning, and thinking skills. It is the most common type of dementia. Neurodegenerative disorders are considered a major burden on the healthcare system and one of the major causes of disabilities across the globe. The prevalence of neurogenerative disorders is increasing owing to factors such as aging, traumatic brain injury, genetic factors, stress, and other lifestyle risk factors. According to Alzheimer's Association (U.S.), a non-profit organization focused on Alzheimer’s disease care, research, and support, in 2025, the prevalence of Alzheimer’s disease increased to 6.9 million in age 65 and older population from 6.2 million in 2021. Thus, the rising prevalence of Alzheimer’s disease is expected to increase the demand for Alzheimer’s drugs.
Increase in Research Funding
The increasing prevalence of Alzheimer’s disease leads to the rising need for novel therapies for its treatment. Many public and private players provide funding for Alzheimer’s disease research to understand the disease pathology and develop the drug accordingly. According to the Alzheimer’s Association (U.S.), Alzheimer's and dementia research funding at the National Institutes of Health (NIH) reached USD 3.8 billion in 2024 from USD 2.8 billion in 2021. Some of the recent funding are as follows:
- In May 2025, NeuroTherapia (U.S.), a clinical trial pharmaceutical company, received a grant from the Alzheimer's Association as part of the cloud program to develop its NTRX-07 drug for the treatment of Alzheimer's disease (AD).
- In October 2024, the National Institute on Aging, part of the National Institutes of Health, provided funding of USD 151 million to the University of California San Francisco for the clinical trial of Alzheimer’s disease. The UCSF-led trial will combine an anti-amyloid with tau therapies to arrest disease progression.
Table of contents
10 chapters · 107 sections · 200 pages · click to expandSegmental analysis
| Segment | Largest share (2025) | Fastest growth (2025–2032) |
|---|---|---|
| By Drug Type | Cholinesterase Inhibitors | — |
| By Application | Symptoms Management | — |
By Drug Type
- The Alzheimer’s drugs market is segmented into cholinesterase inhibitors, NMDA receptor antagonists, glutamate regulators, and combination drugs.
- The cholinesterase inhibitors segment is expected to account for the largest share of 46.9% of the Alzheimer’s drugs market.
- The drug works by decreasing the breakdown of acetylcholine, thus helping in the improvement of cognitive functions.
- The rising prevalence of Alzheimer’s disease and the increasing aging population are contributing to the demand for Cholinesterase inhibitors.
- The large share of the segment can be attributed to the high usage of these drugs for Alzheimer's treatment and the high number of drugs approved under this segment.
- At present, galantamine, donepezil, rivastigmine, and others are currently approved for the treatment of mild-to-moderate Alzheimer's disease (AD).
- Several studies have proven their efficacy for the treatment of the disease.
- According to an article published in the National Library of Medicine in 2022, cholinesterase inhibitors can slightly delay the loss of brain function in people who have mild to moderate Alzheimer’s disease.
By Application
- The Alzheimer’s drugs market is segmented into disease progression and symptom management.
- The symptoms management segment is expected to account for the largest share of 87.2% of the Alzheimer’s drugs market.
- Symptom management is considered an important step in Alzheimer’s disease treatment.
- The majority of the drugs used in the treatment of Alzheimer’s disease are for symptom management, thus contributing to the largest share of the segment.
- The symptom management drugs slow down the process of disease progression, thus helping in reducing the healthcare cost associated with it, thus increasing demand.
- Alzheimer's disease symptoms such as impaired judgment, memory loss, language loss, and other brain changes can make it harder to manage other health conditions, which can create further complications.
- Hence, the demand for symptom management is expected to increase.
Geographic analysis
North America
Largest shareIn 2025, North America is expected to account for the largest share of the 43.0% of Alzheimer’s drugs market. The large share of the region is attributed to the increasing prevalence of Alzheimer’s disease, increasing funding for the development of Alzheimer’s treatment, the presence of key players, the rising number of clinical trials for Alzheimer’s drugs, and favorable reimbursement policies. For instance, in February 2025, the Centers for Medicare & Medicaid Services (U.S.), a federal agency within the United States Department of Health and Human Services that administers the Medicare program, covered a recently approved medication Leqembi (Lecanemab) used in the treatment of Alzheimer’s diseases. The drug is developed in partnership with Eisai Co., Ltd. (Japan) and Biogen Inc. (U.S.). North America to Dominate the Market
Asia-Pacific
Fastest growthMoreover, the market in Asia-Pacific is slated to register the highest growth rate of 11.4% during the forecast period. The countries in the region, including China, India, and South Korea, are expected to offer significant opportunities for market growth. The growth in the country market is attributed to the growing pharmaceutical industry, supporting government initiatives, and a large number of clinical trials conducted in the region for Alzheimer’s. Also, government bodies in the region are providing funds for research on Alzheimer’s disease, which is driving the market’s growth. For instance, in August 2024, Bredis Healthcare (South Korea) received funding of USD 1.27 million for the development of diagnostic tests for Alzheimer's disease. The funding is provided by the South Korean Ministry of SMEs and Startups as a part of the Deep Tech Incubator Program for Startups (TIPS). Similarly, in May 2022, the Indian Health Service provided funding of USD 5 million to support urban Indian organizations, tribes, and tribal organizations to develop sustainable and comprehensive approaches to addressing Alzheimer’s disease.
Competitive landscape
- July 2024
The U.S. FDA approved lecanemab through the Accelerated Approval Pathway for the treatment of Alzheimer’s disease. Lecanemab removes a sticky protein from the brain that is believed to cause Alzheimer’s disease progression. Eisai Co., Ltd. (Japan) and Biogen Inc. (U.S.) developed the drug in partnership.
- December 2022
Eisai Co., Ltd. (Japan) collaborated with Washington University School of Medicine (U.S.) for the development of novel treatments for neurodegenerative disorders, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
- March 2022
Corium, Inc. (U.S.) received U.S. FDA approval for ADLARITY (donepezil transdermal system) for the treatment of patients with Alzheimer’s disease. ADLARITY is a once-weekly patch to continuously deliver consistent doses of donepezil through the skin.
- Biogen (U.S.)
- Novartis AG · Switzerland
- F. Hoffmann-La Roche AG · Switzerland
- AbbVie Inc. (U.S.)
- Teva Pharmaceutical Industries Ltd. · Israel
- Eisai Co., Ltd. · Japan
- SUPERNUS PHARMACEUTICALS, INC. (U.S.)
- H. Lundbeck A/S · Denmark
- AC Immune SA · Switzerland
- Zydus Lifesciences Limited · India
- Johnson & Johnson (U.S.)
- Daiichi Sankyo Company · Japan
Frequently asked questions
The Alzheimer’s drugs market report covers the qualitative and quantitative analysis of the market. It involves analyzing various market segments of Alzheimer’s drugs, such as type, source, production process, and end user, at the regional and country levels. The report also provides insights on factors impacting market growth, regulatory analysis, pipeline analysis, and Porter’s five forces analysis.
Cite this report
Meticulous Research. (2024). Alzheimer’s Drugs Market - Global Opportunity Analysis and Industry Forecast (2025-2032) (Report No. MR-1264). Meticulous Market Research Pvt. Ltd. https://www.meticulousresearch.com/product/alzheimers-drugs-market-5947